M
Min Qiu
Researcher at Tufts University
Publications - 9
Citations - 396
Min Qiu is an academic researcher from Tufts University. The author has contributed to research in topics: In vivo & Medicine. The author has an hindex of 4, co-authored 6 publications receiving 39 citations.
Papers
More filters
Journal ArticleDOI
Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3.
Min Qiu,Zachary Glass,Jinjin Chen,Mary E. Haas,Xin Jin,Xuewei Zhao,Xuehui Rui,Zhongfeng Ye,Yamin Li,Feng Zhang,Qiaobing Xu +10 more
TL;DR: In this article, a lipid nanoparticle delivery platform carrying Cas9 messenger RNA (mRNA) and guide RNA for CRISPR-Cas9-based genome editing of Angiopoietin-like 3 (Angptl3) was developed.
Journal ArticleDOI
Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis
Min Qiu,Yan Tang,Jinjin Chen,Rachel E. Muriph,Zhongfeng Ye,Changfeng Huang,Jason Evans,Elizabeth P. Henske,Qiaobing Xu +8 more
TL;DR: The success of LNP-based RNA therapy in a preclinical model of lymphangioleiomyomatosis (LAM), a destructive lung disease caused by loss-of-function mutations in the Tsc2 gene, is demonstrated and establishes mRNA LNPs as a promising therapeutic intervention for the treatment of LAM.
Journal ArticleDOI
Imidazole‐Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes
TL;DR: This paper investigated a library of synthetic lipid-like molecules (lipidoids) for their capability of delivering mRNA into primary T lymphocytes both ex vivo and in vivo and identified imidazole-containing lipidoids that are particularly potent in T lymphocyte transfection.
Journal ArticleDOI
Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
TL;DR: In this article, the authors highlight key advances in designing and developing combinatorial synthetic lipid nanoparticles (LNPs) with distinct chemical structures and properties for in vitro and in vivo intracellular mRNA delivery.
Journal ArticleDOI
Lipid nanoparticle-mediated lymph node–targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response
TL;DR: The enhanced antitumor efficacy of the endogenously LN-targeting lipid nanoparticle (LNP) system shows great potential as a universal platform for the next generation of mRNA vaccines.